LIPELLA PHARMACEUTICALS INC (LIPO) Stock Price, Quote, News and Overview
NASDAQ:LIPO - Nasdaq - US53630L2097 - Common Stock - Currency: USD
LIPO Quote, Performance and Key Statistics
2.65
+0.07 (+2.71%)
The current stock price of LIPO is 2.65 USD. In the past month the price decreased by -2.57%. In the past year, price decreased by -53.41%.
LIPO Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.39 | 329.14B | ||
| AMGN | AMGEN INC | 14.17 | 150.99B | ||
| GILD | GILEAD SCIENCES INC | 13.33 | 128.61B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1702.9 | 126.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.2 | 65.88B | ||
| ARGX | ARGENX SE - ADR | 330.52 | 37.54B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.72B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.39B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.52B | ||
| NTRA | NATERA INC | N/A | 20.79B | ||
| BIIB | BIOGEN INC | 7.22 | 17.39B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.30B |
Related stock screener links
About LIPO
Company Profile
Lipella Pharmaceuticals, Inc. develops and commercializes lipid-based therapies for common bladder syndromes. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 5 full-time employees. The company went IPO on 2022-12-20. The firm is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The firm is addressing two indications via the development of its product candidates, which it has designated as LP-10 for the indication of hemorrhagic cystitis (HC) and LP-310 for the indication of oral lichen planus (OLP), which is chronic, uncontrolled urinary blood loss that results from certain chemotherapies (such as alkylating agents) or pelvic radiation therapy (also called radiation cystitis). In the third program, the Company is also developing an oral, liposomal formulation of tacrolimus, LP-410, for the treatment of oral graft-versus-host disease (GVHD). In a fourth program, the Company is also developing an intravesical formulation of immunoglobulins including checkpoint inhibitors, referred to as LP-50.
Company Info
LIPELLA PHARMACEUTICALS INC
400 N Lexington St Ste LL103
Pittsburgh PENNSYLVANIA US
Employees: 5
Company Website: https://lipella.com/
Investor Relations: https://lipella.com/investors/
Phone: 14129010315
LIPELLA PHARMACEUTICALS INC / LIPO FAQ
What is the stock price of LIPELLA PHARMACEUTICALS INC today?
The current stock price of LIPO is 2.65 USD. The price increased by 2.71% in the last trading session.
What is the ticker symbol for LIPELLA PHARMACEUTICALS INC stock?
The exchange symbol of LIPELLA PHARMACEUTICALS INC is LIPO and it is listed on the Nasdaq exchange.
On which exchange is LIPO stock listed?
LIPO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for LIPELLA PHARMACEUTICALS INC stock?
7 analysts have analysed LIPO and the average price target is 10.2 USD. This implies a price increase of 284.91% is expected in the next year compared to the current price of 2.65. Check the LIPELLA PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is LIPELLA PHARMACEUTICALS INC worth?
LIPELLA PHARMACEUTICALS INC (LIPO) has a market capitalization of 6.76M USD. This makes LIPO a Nano Cap stock.
How many employees does LIPELLA PHARMACEUTICALS INC have?
LIPELLA PHARMACEUTICALS INC (LIPO) currently has 5 employees.
What are the support and resistance levels for LIPELLA PHARMACEUTICALS INC (LIPO) stock?
LIPELLA PHARMACEUTICALS INC (LIPO) has a support level at 2.36 and a resistance level at 3.07. Check the full technical report for a detailed analysis of LIPO support and resistance levels.
Is LIPELLA PHARMACEUTICALS INC (LIPO) expected to grow?
The Revenue of LIPELLA PHARMACEUTICALS INC (LIPO) is expected to decline by -100% in the next year. Check the estimates tab for more information on the LIPO EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy LIPELLA PHARMACEUTICALS INC (LIPO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of LIPO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of LIPO, evaluating the profitability, health, valuation and growth aspects
- LIPELLA PHARMACEUTICALS INC (LIPO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- LIPELLA PHARMACEUTICALS INC (LIPO) Sales and EPS estimates to see what analysts future expectations are.
- LIPELLA PHARMACEUTICALS INC (LIPO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- LIPELLA PHARMACEUTICALS INC (LIPO) Insider and Institutional Ownership to learn about the owners and their transactions.
- LIPELLA PHARMACEUTICALS INC (LIPO) Stock Chart to make your own analysis
- LIPELLA PHARMACEUTICALS INC (LIPO) Latest news and press-releases to stay up to date.
Does LIPELLA PHARMACEUTICALS INC (LIPO) stock pay dividends?
LIPO does not pay a dividend.
What is the Price/Earnings (PE) ratio of LIPELLA PHARMACEUTICALS INC (LIPO)?
LIPELLA PHARMACEUTICALS INC (LIPO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.78).
What is the Short Interest ratio of LIPELLA PHARMACEUTICALS INC (LIPO) stock?
The outstanding short interest for LIPELLA PHARMACEUTICALS INC (LIPO) is 0.89% of its float. Check the ownership tab for more information on the LIPO short interest.
LIPO Technical Analysis
LIPO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to LIPO. LIPO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
LIPO Financial Highlights
Over the last trailing twelve months LIPO reported a non-GAAP Earnings per Share(EPS) of -4.78. The EPS decreased by -219.08% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -187.6% | ||
| ROE | -261.33% | ||
| Debt/Equity | 0 |
LIPO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to LIPO. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 33.76% and a revenue growth -100% for LIPO